Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1484 alone and with pembrolizumab in adults with solid tumors
NL-OMON59009Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of MK-1484 and pembrolizumab in Nonhematologic neoplasms (2 arms), sponsored by Merck & Co. Started Jun 2022; status: completed.
02
Drugs
MK-1484pembrolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59009.